Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 M537I FGFR2 V564L FGFR2 amp||cholangiocarcinoma||predicted - resistant||Infigratinib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with cholangiocarcinoma with amplification of FGFR2 experienced disease progression after 3.9 months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, M537I and V564L (PMID: 34250419).||34250419|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|